These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Endocannabinoid inhibition: a new cardioprotective strategy against doxorubicin cardiotoxicity. Fajardo G; Bernstein D J Am Coll Cardiol; 2007 Aug; 50(6):537-9. PubMed ID: 17678737 [No Abstract] [Full Text] [Related]
7. [Pharmacology of cannabinoid receptors]. Le Fur G; Rinaldi-Carmona M; Barth F; Alexander J Bull Acad Natl Med; 2007; 191(4-5):933-8; discussion 938-40. PubMed ID: 18225447 [TBL] [Abstract][Full Text] [Related]
8. Rimonabant induces partial seizures in a patient with a history of generalized epilepsy. Braakman HM; van Oostenbrugge RJ; van Kranen-Mastenbroek VH; de Krom MC Epilepsia; 2009 Sep; 50(9):2171-2. PubMed ID: 19706063 [No Abstract] [Full Text] [Related]
9. Endocannabinoids--the brain's own marijuana--may be linked to the metabolic syndrome. Griffing GT MedGenMed; 2006 Oct; 8(4):7. PubMed ID: 17415289 [No Abstract] [Full Text] [Related]
10. The element of surprise. Piomelli D Nat Med; 2008 Jul; 14(7):720-1. PubMed ID: 18607371 [No Abstract] [Full Text] [Related]
11. Rimonabant as potential treatment for the neglected epidemic of diabetes in the Middle East and Arabian Peninsula. Implication for prevention. Ahmed MH Saudi Med J; 2007 May; 28(5):806-8. PubMed ID: 17457461 [No Abstract] [Full Text] [Related]
12. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system]. Ducobu J; Sternon J J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510 [TBL] [Abstract][Full Text] [Related]
13. [The role of the cannabinoid system in the pathogenesis and treatment of alcohol dependence]. Pietrzak B; Dunaj A; Piątkowska K Postepy Hig Med Dosw (Online); 2011 Sep; 65():606-15. PubMed ID: 21934185 [TBL] [Abstract][Full Text] [Related]
15. Rimonabant in obese patients with type 2 diabetes. Randall MD; Kendall DA; Bennett AJ; O'Sullivan SE Lancet; 2007 Feb; 369(9561):555. PubMed ID: 17307094 [No Abstract] [Full Text] [Related]
16. Rimonabant in obese patients with type 2 diabetes. Shapiro H; Singer P Lancet; 2007 Feb; 369(9561):553-4; author reply 554-5. PubMed ID: 17307091 [No Abstract] [Full Text] [Related]
17. [Endocannabinoids--the new option in the treatment of metabolic syndrome and in smoking cessation]. Kvasnicka T Cas Lek Cesk; 2005; 144(2):81-4; discussion 85. PubMed ID: 15807291 [TBL] [Abstract][Full Text] [Related]
18. Cannabinoid receptor antagonists and the metabolic syndrome: Novel promising therapeutical approaches. Cervino C; Pasquali R; Pagotto U Mini Rev Med Chem; 2007 Jan; 7(1):21-30. PubMed ID: 17266634 [TBL] [Abstract][Full Text] [Related]
19. [Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management]. Bramlage P; Böcking W; Kirch W Dtsch Med Wochenschr; 2005 Mar; 130(12):665-8. PubMed ID: 15776349 [TBL] [Abstract][Full Text] [Related]
20. [Impact of endocannabinoid system in modulation of cardiometabolic risk factors]. Sulcová A Vnitr Lek; 2006 Jun; 52(6):615-8. PubMed ID: 16871766 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]